Takeda works on drug to treat COVID complications

Universities collaborate on medicine that might prevent blood vessel inflammation

Researchers at Takeda Pharmaceutical and two Japanese universities hope to bring their drug to market in a few years.

YUTA TAKAGI, Nikkei staff writer

January 31, 2021 12:40 JST

TOKYO -- Takeda Pharmaceutical and two Japanese universities are developing a drug to treat the clogging and inflammation of blood vessels, complications of COVID-19.

The drug uses a mechanism different from those of existing coronavirus drugs, and the developers report that it will likely help prevent the aggravation of COVID-19 symptoms.